More details about statins for prevention of heart attack

Statins are drugs, which obstruct the enzyme HMG-CoA (3-hydroxy-3-methylglutaryl-coenzyme A) reductase. This enzyme defines the speed of the synthesis of cholesterol in liver cells - hepatocytes. Since there is a lack of cholesterol in hepatocytes after taking statins, which is necessary for the production of bile acid, the number of LDL (low-density lipoproteins) receptors increases on the surfaces of hepatocytes. This are necessary for pumping cholesterol out from the blood into the liver cells and in this way reduces the concentration of cholesterol in the blood, which is an important factor in arteriolosclerosis. Statins also reduce the formation of VDRL (very low-density lipoprotein), which is the primary transmitter of triglycerides in the blood. Satins have other protective characteristics as well for arterial walls, which hare not directly related to the reduction of fat tin the blood.

KIF6 is a gene, which contains a record for albumen (kinesin-like protein 6). This albumen helps in the transport of other albumen in the cell. Research showed that already a small variance or polymorphism of this gene in location rs20455 has a significant impact on the risk for the recurring heart attacks (MI) or cardiovascular diseases. On the other hand, the research on 4480 individuals showed that carriers of the genotype rs20455 (C;C) or rs20455 (C;T) greater protection from a recurring heart attack or coronary heart disease, if they take pravastatin than those who are carriers of the genotype rs20455 (T;T).

Back to basic description